Developing Innovative Therapies for Use in Medically Supervised Settings

Read More

About AcelRx

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings.


When delivered sublingually, sufentanil has shown a more consistent pharmacokinetic profile and avoids the high peak plasma levels and short duration of action seen with intravenous administration.1 This makes it a promising candidate for treating moderate-to-severe acute pain non-invasively. To learn more about the novel pharmacokinetics of sublingual sufentanil, watch the MOA video on the sufentanil page.

proprietary sublingual technology

The Company's two late-stage product candidates, DSUVIATM and Zalviso®, were developed using this proprietary technology.

Learn More

  1. Minkowitz, H.S. et al. Pharmacokinetics of sublingual sufentanil tablets and efficacy and safety in the management of postoperative pain. Reg Anesth Pain Med. 2013 Mar-Apr;38(2):131-9.